Division of Allergy and Immunology, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, 3333 Burnet Avenue, ML2010, Cincinnati, OH 45229-3039, USA.
Expert Rev Clin Immunol. 2011 Jul;7(4):411-7. doi: 10.1586/eci.11.27.
Mepolizumab (Bosatria(®), GlaxoSmithKline) is a biologic agent developed to treat asthma. It represents a humanized monoclonal antibody of IgG1 κ type, which targets human IL-5 and thus prevents its interaction with the α-chain of the IL-5 receptor. To date, it has not been approved for use in any eosinophil-related disorder; however, several studies have suggested some therapeutic benefit across a spectrum of eosinophil-related disorders. This article evaluates the currently available preclinical and clinical studies, and the impact of mepolizumab against a variety of eosinophilic disorders.
美泊利珠单抗（Bosatria(®)，葛兰素史克）是一种生物制剂，用于治疗哮喘。它是一种人源化 IgG1 κ 单克隆抗体，靶向人白细胞介素 5（IL-5），从而阻止其与 IL-5 受体的 α 链相互作用。迄今为止，它尚未被批准用于任何与嗜酸性粒细胞相关的疾病；然而，一些研究表明，它在一系列与嗜酸性粒细胞相关的疾病中具有一定的治疗益处。本文评估了美泊利珠单抗目前可用的临床前和临床研究，以及其对各种嗜酸性粒细胞疾病的治疗作用。
